MGAT5 alters the severity of multiple sclerosis

B. Brynedal, J. Wojcik, F. Esposito, V. Debailleul, J. Yaouanq, F. Martinelli-Boneschi, G. Edan, G. Comi, J. Hillert, H. Abderrahim

    Research output: Contribution to journalArticle

    47 Citations (Scopus)

    Abstract

    Multiple Sclerosis (MS) is a genetically complex immune mediated, demyelinating disease of the central nervous system. To date no genetic variants have been unambiguously linked to disease severity. We have conducted a genome wide screen, using Affymetrix Genechip® 500K technology, for severity in 1040 MS patients. Two markers within MGAT5, a gene coding for a glycosylation enzyme, were found to be significantly associated with outcome in the screening as well as in an independent population (combined p-values: 2.8 × 10- 6 and 1.5 × 10- 7).

    Original languageEnglish
    Pages (from-to)120-124
    Number of pages5
    JournalJournal of Neuroimmunology
    Volume220
    Issue number1-2
    DOIs
    Publication statusPublished - 30 Mar 2010

      Fingerprint

    Keywords

    • Genetic association
    • MGAT5
    • MSSS
    • Multiple sclerosis
    • Severity

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology
    • Neurology
    • Clinical Neurology

    Cite this

    Brynedal, B., Wojcik, J., Esposito, F., Debailleul, V., Yaouanq, J., Martinelli-Boneschi, F., Edan, G., Comi, G., Hillert, J., & Abderrahim, H. (2010). MGAT5 alters the severity of multiple sclerosis. Journal of Neuroimmunology, 220(1-2), 120-124. https://doi.org/10.1016/j.jneuroim.2010.01.003